Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jul 12, 2022 5:23pm
152 Views
Post# 34819212

RE:RE:RE:RE:Time for action

RE:RE:RE:RE:Time for actionI put an article published in China "nicked"!The never ending issue with THTX is lack of coverage so my point wasn't so much the content of the article but exposure it can create. First they have to create that exposure then they can materialize on the audience the exposure brings so any meaningful progress communicated by the company creates  the buzz it deserves among investors.
Their flowers on Stocktwits has been about 900 versus other Canadian companies with thousands of followers.Again after the long wait at the end of phase1a all CMO said was our MTD is x and results are similar to preclinical nothing from CEO? Why such a low profile?
qwerty22 wrote:

It's really not great timing though. If we take what juniper said about 3 SD patients. Even though they are fine, they aren't reportable. SD after 2 cycles is not something you can chalk up to the drugs effect. They might get their next scan in the coming weeeks which at best would deliver an unconfirmed response and then it's 2 more cycles(6 weeks) to the next scan before there is the potential for a confirmed response. All that is assuming the best from those patients. None of that can be avoided. So assuming Juniper is correct then that's the best we can expect from the 1b patients from Karmanos. The other centre are likely similar. In my view it's really difficult to say much without confirmed responses. 

So probably the only hope for something on Thursday would be if one of the last 6 patients from 1a showed something. Getting meaningful positive info, the stuff we really want to hear, probably hangs on that thread.

I think SPCEO is right Aug/Sept are more reasonable. It's a long wait until then. 

 

realitycheck4u wrote: LOL. It's easy to be frustrated, and most of us here are not patient enough, from the belief that we want to hear news and more information sooner rather than later. It's hard for most of us to be anything but upset. However, you either think they can deliver and TH1902 can be successful, and that they can explain the current status and the current situation, or you don't.  We can draw some conclusions from what happens on Thursday.

I beleive they need to do all they can to start to move the needle. To do that, they need to disclose what they can (or should) and explain it without any holes in it. They know that. They anguish about it likely as much as we do. So, let's see what happens.
 

 

qwerty22 wrote:

We've found our leader!

 

Trogarzon wrote: Since this management has'nt provided a normal liquidity and decent valuation for the company shares, I am asking Soleus and others to pull together to draw some serious action from the BOD... total mess for shareholders... no way out.  How do you sell 1m shares without hitting the bid at 20 cents..

 

 


 




<< Previous
Bullboard Posts
Next >>